Table 3.
SABA prescriptions in the 12 months before the study visit.
| SABA prescriptions in the previous 12 months | All (N = 3066)a | Primary care (n = 559) |
Specialists (n = 2498) |
||||
|---|---|---|---|---|---|---|---|
| Investigator-classified mild asthma (n = 260) | Investigator-classified moderate-to-severe asthma (n = 299) | All (n = 559) | Investigator-classified mild asthma (n = 289) | Investigator-classified moderate-to-severe asthma (n = 2209) | All (n = 2498) | ||
| Number of patients prescribed inhaled SABA monotherapy | |||||||
| Yes | 89 (2.9) | 45 (17.3) | 0 (0.0) | 45 (8.1) | 43 (14.9) | 1 (0.0) | 44 (1.8) |
| No | 2977 (97.1) | 215 (82.7) | 299 (100) | 514 (91.9) | 246 (85.1) | 2208 (100) | 2454 (98.2) |
| Number of canisters/inhalers prescribed per patient 12 months before the study visit | |||||||
| n | 85 | 42 | NA | 42 | 42 | 1 | 43 |
| Mean (SD) | 4.0 (4.6) | 5.0 (5.6) | NA | 5.0 (5.6) | 3.1 (3.1) | 3.0 (NA) | 3.1 (3.0) |
| Median (min, max) | 2.0 (1.0, 16.0) | 2.0 (1.0, 16.0) | NA | 2.0 (1.0, 16.0) | 2.0 (1.0, 12.0) | 3.0 (3.0, 3.0) | 2.0 (1.0, 12.0) |
| Missing data | 4 (4.5) | 3 (6.7) | NA | 3 (6.7) | 1 (2.3) | 0 (0.0) | 1 (2.3) |
| Number of canisters/inhalers prescribed per patient 12 months before the study visit by category | |||||||
| 1–2 | 50 (58.8) | 24 (57.1) | NA | 24 (57.1) | 26 (61.9) | 0 (0.0) | 26 (60.5) |
| 3–5 | 18 (21.2) | 5 (11.9) | NA | 5 (11.9) | 12 (28.6) | 1 (100) | 13 (30.2) |
| 6–9 | 4 (4.7) | 4 (9.5) | NA | 4 (9.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 10–12 | 6 (7.1) | 2 (4.8) | NA | 2 (4.8) | 4 (9.5) | 0 (0.0) | 4 (9.3) |
| ≥13 | 7 (8.2) | 7 (16.7) | NA | 7 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing data (n) | 4 | 3 | NA | 3 | 1 | 0 | 1 |
| Total | 85 | 42 | NA | 42 | 42 | 1 | 43 |
| Number of patients prescribed inhaled SABA in addition to maintenance therapy | |||||||
| Yes | 1594 (52.0) | 157 (60.4) | 138 (46.2) | 295 (52.8) | 129 (44.6) | 1169 (52.9) | 1298 (52) |
| No | 1472 (48.0) | 103 (39.6) | 161 (53.8) | 264 (47.2) | 160 (55.4) | 1040 (47.1) | 1200 (48) |
| Number of canisters/inhalers prescribed per patient 12 months before the study visit | |||||||
| n | 1531 | 156 | 110 | 266 | 126 | 1138 | 1264 |
| Mean (SD) | 5.1 (10.6) | 4.6 (4.7) | 5.1 (20.1) | 4.8 (13.4) | 2.9 (2.8) | 5.4 (10.4) | 5.1 (10.0) |
| Median (min, max) | 2.0 (1.0, 210.0) | 3.0 (1.0, 18.0) | 2.0 (1.0, 210.0) | 2.0 (1.0, 210.0) | 2.0 (1.0, 16.0) | 3.0 (1.0, 196.0) | 3.0 (1.0, 196.0) |
| Missing data | 63 (4.0) | 1 (0.6) | 28 (20.3) | 29 (9.8) | 3 (2.3) | 31 (2.7) | 34 (2.6) |
| Number of canisters/inhalers prescribed per patient 12 months before the study visit by category | |||||||
| 1–2 | 766 (50.0) | 76 (48.7) | 71 (64.5) | 147 (55.3) | 75 (59.5) | 544 (47.8) | 619 (49.0) |
| 3–5 | 377 (24.6) | 37 (23.7) | 21 (19.1) | 58 (21.8) | 35 (27.8) | 283 (24.9) | 318 (25.2) |
| 6–9 | 199 (13.0) | 18 (11.5) | 7 (6.4) | 25 (9.4) | 10 (7.9) | 164 (14.4) | 174 (13.8) |
| 10–12 | 106 (6.9) | 11 (7.1) | 5 (4.5) | 16 (6.0) | 5 (4.0) | 85 (7.5) | 90 (7.1) |
| ≥13 | 83 (5.4) | 14 (9.0) | 6 (5.5) | 20 (7.5) | 1 (0.8) | 62 (5.4) | 63 (5.0) |
| Missing data (n) | 63 | 1 | 28 | 29 | 3 | 31 | 34 |
| Total | 1531 | 156 | 110 | 266 | 126 | 1138 | 1264 |
| Number of patients prescribed oral SABA | |||||||
| Yes | 83 (2.7) | 13 (5.0) | 12 (4.0) | 25 (4.5) | 5 (1.7) | 53 (2.4) | 58 (2.3) |
| No | 2983 (97.3) | 247 (95.0) | 287 (96.0) | 534 (95.5) | 284 (98.3) | 2156 (97.6) | 2440 (97.7) |
| Number of patients prescribed nebulized SABA | |||||||
| Yes | 224 (7.3) | 80 (30.8) | 51 (17.1) | 131 (23.4) | 20 (6.9) | 73 (3.3) | 93 (3.7) |
| No | 2842 (92.7) | 180 (69.2) | 248 (82.9) | 428 (76.6) | 269 (93.1) | 2136 (96.7) | 2405 (96.3) |
Max, maximum; min, minimum; NA, not available; SABA, short-acting β2-agonist; SD, standard deviation. Data are presented as n (%) unless otherwise specified. Missing data are not included in the calculation of percentages.
a
Practice type was not recorded for 9 patients